In NSCLC, the overexpression of SUR1 (KCNJ8 or Kir6.1) promotes cell proliferation, and silencing KCNJ8 or glibenclamide treatment decreases cell and tumor growth, as well as increasing expression of the tumor suppressor Krüppel-like factor 4 (KLF4) [83]. Here, KCNJ8 is linked to non-small cell lung carcinoma.